1.82 0.05 (2.82%) | 02-19 16:00 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 5.72 ![]() |
1-year : | 8.03 ![]() |
Resists | First : | 4.9 ![]() |
Second : | 6.88 ![]() |
Pivot price | 2.13 ![]() |
|||
Supports | First : | 1.7 ![]() |
Second : | 1.41 ![]() |
MAs | MA(5) : | 1.85 ![]() |
MA(20) : | 2.65 ![]() |
MA(100) : | 18.11 ![]() |
MA(250) : | 51.27 ![]() |
|
MACD | MACD : | -1.4 ![]() |
Signal : | -1.7 ![]() |
%K %D | K(14,3) : | 5.9 ![]() |
D(3) : | 5.4 ![]() |
RSI | RSI(14): 28.5 ![]() |
|||
52-week | High : | 205.6 | Low : | 1.7 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ EYEN ] has closed above bottom band by 30.7%. Bollinger Bands are 87.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 1.86 - 1.87 | 1.87 - 1.88 |
Low: | 1.68 - 1.69 | 1.69 - 1.7 |
Close: | 1.8 - 1.82 | 1.82 - 1.83 |
Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.
Wed, 05 Feb 2025
Revolutionary Eye Drop Spray Shows Perfect Precision: Eyenovia's Game-Changing Solution for Millions - StockTitan
Wed, 05 Feb 2025
Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device - GlobeNewswire
Tue, 28 Jan 2025
Major Shake-up at Eyenovia: Massive 80:1 Share Consolidation Coming February - StockTitan
Tue, 28 Jan 2025
Eyenovia Announces 1-for-80 Reverse Stock Split - GlobeNewswire
Wed, 15 Jan 2025
Eyenovia Announces Leading Proxy Advisory Firms, ISS and - GlobeNewswire
Fri, 06 Dec 2024
Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering - GlobeNewswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 2 (M) |
Held by Insiders | 992240 (%) |
Held by Institutions | 0.8 (%) |
Shares Short | 57 (K) |
Shares Short P.Month | 0 (K) |
EPS | -3.565e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -451 % |
Return on Assets (ttm) | 195.5 % |
Return on Equity (ttm) | -79.7 % |
Qtrly Rev. Growth | 31830 % |
Gross Profit (p.s.) | 28.47 |
Sales Per Share | -310.43 |
EBITDA (p.s.) | -4.52e+006 |
Qtrly Earnings Growth | -55.3 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -30 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | -0.01 |
Price to Cash Flow | 0.66 |
Dividend | 0 |
Forward Dividend | 55850 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |